Monopar Therapeutics (MNPR) Equity Ratio (2016 - 2020)

Monopar Therapeutics' Equity Ratio history spans 5 years, with the latest figure at 0.96 for Q3 2020.

  • For Q3 2020, Equity Ratio rose 6.42% year-over-year to 0.96; the TTM value through Sep 2020 reached 0.96, up 6.42%, while the annual FY2019 figure was 0.95, 0.04% changed from the prior year.
  • Equity Ratio for Q3 2020 was 0.96 at Monopar Therapeutics, up from 0.95 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.98 in Q4 2016 and bottomed at 0.91 in Q3 2019.
  • The 5-year median for Equity Ratio is 0.96 (2018), against an average of 0.95.
  • The largest annual shift saw Equity Ratio dropped 6.15% in 2019 before it increased 6.42% in 2020.
  • A 5-year view of Equity Ratio shows it stood at 0.98 in 2016, then decreased by 0.93% to 0.97 in 2017, then dropped by 2.39% to 0.95 in 2018, then grew by 0.04% to 0.95 in 2019, then rose by 1.87% to 0.96 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Equity Ratio are 0.96 (Q3 2020), 0.95 (Q2 2020), and 0.97 (Q1 2020).